TISSUE REGENIX GROUP PLC - ORD 0.1P
TISSUE REGENIX GROUP PLC - ORD 0.1P
Share · GB00B5SGVL29 (XLON)
Overview Financial Indicators
0,32 GBP
0,63 % 0,002 GBP
Closing Price XLON 06.06.2025: 31,70 GBX
London (XLON) · Current prices and charts at MoneyPeak
06.06.2025 14:49

Current Prices from TISSUE REGENIX GROUP PLC - ORD 0.1P

ExchangeTickerCurrencyLast TradePriceDaily Change
XLON: London
London
TRX.L
GBX
06.06.2025 14:49
31,70 GBX
31,10 GBX
+1,93 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % -0,94 % -3,94 % -23,06 % -44,39 % -53,72 % -14,32 %

Company Profile for TISSUE REGENIX GROUP PLC - ORD 0.1P Share

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

Company Data

Name TISSUE REGENIX GROUP PLC - ORD 0.1P
Company Tissue Regenix Group plc
Website https://www.tissueregenix.com
Primary Exchange XLON London
ISIN GB00B5SGVL29
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Daniel Ray Lee
Market Capitalization 26 Mio
Country United Kingdom
Currency GBP
Employees 0,1 T
Address Unit 3, LS25 2GY Garforth
IPO Date 2006-12-21

Stock Splits

Date Split
28.04.2023 1:100
29.06.2010 1:5

Ticker Symbols

Name Symbol
London TRX.L

More Shares

Investors who TISSUE REGENIX GROUP PLC - ORD 0.1P hold also have the following shares in their portfolio:
Samfine Creation Holdings Group Limited - Class A Ordinary Share
Samfine Creation Holdings Group Limited - Class A Ordinary Share Share
XTR.II HARV.CH.GOV.BD 1D
XTR.II HARV.CH.GOV.BD 1D ETF
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025